Free Trial
NASDAQ:CLPT

ClearPoint Neuro (CLPT) Stock Price, News & Analysis

ClearPoint Neuro logo
$11.15 +0.19 (+1.73%)
(As of 03:00 PM ET)

About ClearPoint Neuro Stock (NASDAQ:CLPT)

Key Stats

Today's Range
$10.85
$11.18
50-Day Range
$10.74
$13.46
52-Week Range
$5.11
$14.13
Volume
60,089 shs
Average Volume
188,354 shs
Market Capitalization
$307.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33
Consensus Rating
Buy

Company Overview

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

ClearPoint Neuro Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
15th Percentile Overall Score

CLPT MarketRank™: 

ClearPoint Neuro scored higher than 15% of companies evaluated by MarketBeat, and ranked 896th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ClearPoint Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ClearPoint Neuro has only been the subject of 1 research reports in the past 90 days.

  • Read more about ClearPoint Neuro's stock forecast and price target.
  • Earnings Growth

    Earnings for ClearPoint Neuro are expected to grow in the coming year, from ($0.66) to ($0.59) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ClearPoint Neuro is -16.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ClearPoint Neuro is -16.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ClearPoint Neuro has a P/B Ratio of 10.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about ClearPoint Neuro's valuation and earnings.
  • Percentage of Shares Shorted

    2.49% of the outstanding shares of ClearPoint Neuro have been sold short.
  • Short Interest Ratio / Days to Cover

    ClearPoint Neuro has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ClearPoint Neuro has recently decreased by 3.45%, indicating that investor sentiment is improving.
  • Dividend Yield

    ClearPoint Neuro does not currently pay a dividend.

  • Dividend Growth

    ClearPoint Neuro does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.49% of the outstanding shares of ClearPoint Neuro have been sold short.
  • Short Interest Ratio / Days to Cover

    ClearPoint Neuro has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ClearPoint Neuro has recently decreased by 3.45%, indicating that investor sentiment is improving.
  • News Sentiment

    ClearPoint Neuro has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for ClearPoint Neuro this week, compared to 2 articles on an average week.
  • Search Interest

    Only 6 people have searched for CLPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added ClearPoint Neuro to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ClearPoint Neuro insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.11% of the stock of ClearPoint Neuro is held by insiders.

  • Percentage Held by Institutions

    Only 30.08% of the stock of ClearPoint Neuro is held by institutions.

  • Read more about ClearPoint Neuro's insider trading history.
Receive CLPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ClearPoint Neuro and its competitors with MarketBeat's FREE daily newsletter.

CLPT Stock News Headlines

ClearPoint Neuro (CLPT) Receives a Buy from Lake Street
ClearPoint Neuro announces SmartFlow Neuro Cannula FDA authorization
[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
ClearPoint Neuro: Near-Term Volatility Is No Concern
ClearPoint Neuro Achieves Record Q3 Revenue Growth
ClearPoint Neuro trading halted, volatility trading pause
See More Headlines

CLPT Stock Analysis - Frequently Asked Questions

ClearPoint Neuro's stock was trading at $6.79 at the beginning of the year. Since then, CLPT shares have increased by 64.5% and is now trading at $11.17.
View the best growth stocks for 2024 here
.

ClearPoint Neuro, Inc. (NASDAQ:CLPT) posted its earnings results on Wednesday, August, 7th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. The firm earned $7.86 million during the quarter, compared to analyst estimates of $7.50 million. ClearPoint Neuro had a negative trailing twelve-month return on equity of 62.10% and a negative net margin of 59.64%.

ClearPoint Neuro's top institutional shareholders include Essex Investment Management Co. LLC (1.69%), Taylor Frigon Capital Management LLC (1.37%), Geode Capital Management LLC (1.04%) and Conway Capital Management Inc. (0.51%).
View institutional ownership trends
.

Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ClearPoint Neuro investors own include Arista Networks (ANET), NVIDIA (NVDA), CrowdStrike (CRWD), Axon Enterprise (AXON), Advanced Micro Devices (AMD), Cadence Design Systems (CDNS) and Broadcom (AVGO).

Company Calendar

Last Earnings
8/07/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/11/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:CLPT
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.33
High Stock Price Target
$15.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+3.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-22,090,000.00
Pretax Margin
-59.64%

Debt

Sales & Book Value

Annual Sales
$23.95 million
Book Value
$1.05 per share

Miscellaneous

Free Float
25,900,000
Market Cap
$302.28 million
Optionable
Optionable
Beta
1.10
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:CLPT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners